Yanguang Cao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4298920/publications.pdf

Version: 2024-02-01

42 papers	1,125 citations	516215 16 h-index	414034 32 g-index
53 all docs	53 docs citations	53 times ranked	1417 citing authors

#	Article	IF	Citations
1	Applications of minimal physiologically-based pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 711-723.	0.8	144
2	Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 597-607.	0.8	123
3	Physiologically Based Pharmacokinetic Modeling of Nanoparticles. Journal of Pharmaceutical Sciences, 2019, 108, 58-72.	1.6	105
4	Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 375-387.	0.8	69
5	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. Clinical and Translational Science, 2017, 10, 443-454.	1.5	55
6	Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharmaceutical Research, 2015, 32, 3269-3281.	1.7	53
7	Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG. Journal of Controlled Release, 2019, 311-312, 138-146.	4.8	53
8	Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs. Pharmaceutics, 2019, 11, 110.	2.0	49
9	Modelâ€Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ€T Cells in Humans. Clinical Pharmacology and Therapeutics, 2021, 109, 716-727.	2.3	49
10	Depletion of PD-1-positive cells ameliorates autoimmune disease. Nature Biomedical Engineering, 2019, 3, 292-305.	11.6	48
11	Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of Pharmaceutical Sciences, 2020, 109, 3574-3578.	1.6	37
12	Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 571-580.	0.8	34
13	A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts. Pharmaceutical Research, 2018, 35, 174.	1.7	33
14	Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats. Pharmaceutical Research, 2012, 29, 1078-1086.	1.7	21
15	In Translation: FcRn across the Therapeutic Spectrum. International Journal of Molecular Sciences, 2021, 22, 3048.	1.8	21
16	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Advanced Drug Delivery Reviews, 2022, 188, 114421.	6.6	18
17	Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 1-8.	1.3	16
18	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. British Journal of Cancer, 2019, 120, 346-355.	2.9	16

#	Article	IF	Citations
19	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics, 2021, 13, 422.	2.0	16
20	A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K_{on}, K_{off}, endosome trafficking, and animal species. MAbs, 2018, 10, 1322-1331.	2.6	15
21	A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies. AAPS Journal, 2018, 20, 48.	2.2	13
22	A Bioluminescence Resonance Energy Transfer-Based Approach for Determining Antibody-Receptor Occupancy InÂVivo. IScience, 2019, 15, 439-451.	1.9	13
23	Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. Cancer Research, 2020, 80, 591-601.	0.4	13
24	Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer. Cancer Research, 2021, 81, 2522-2533.	0.4	13
25	Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. Drug Metabolism and Disposition, 2019, 47, 155-163.	1.7	11
26	Physiological Considerations for Modeling in vivo Antibody-Target Interactions. Frontiers in Pharmacology, 2022, 13, 856961.	1.6	11
27	A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. Xenobiotica, 2016, 46, 1105-1111.	0.5	10
28	Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 153-164.	2.0	10
29	Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats. Biopharmaceutics and Drug Disposition, 2012, 33, 285-291.	1.1	9
30	Modeling the dynamics of antibodyâ€“target binding in living tumors. Scientific Reports, 2020, 10, 16764.	1.6	8
31	Downregulation of Interferon-Î³ Receptor Expression Endows Resistance to Antiâ€“Programmed Death Protein 1 Therapy in Colorectal Cancer. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 21-28.	1.3	5
32	A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes. Journal of Controlled Release, 2022, 343, 518-527.	4.8	5
33	A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. European Journal of Pharmaceutical Sciences, 2019, 138, 105032.	1.9	4
34	Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes. Mathematical Biosciences and Engineering, 2021, 18, 112-131.	1.0	4
35	Pharmacokinetics of gallic acid and protocatechuic acid in humans after dosing with Relinqing (RLQ) and the potential for RLQ-perpetrated drugâ€“drug interactions on organic anion transporter (OAT) 1/3. Pharmaceutical Biology, 2021, 59, 746-757.	1.3	4
36	Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response. Frontiers in Immunology, 2021, 12, 748768.	2.2	4

#	Article	IF	Citations
37	Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 491-501.	0.8	3
38	Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discovery Today, 2021, 26, 1980-1990.	3.2	3
39	Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery. Bulletin of Mathematical Biology, 2021, 83, 123.	0.9	2
40	Precision drug dosing: A major opportunity for patients and pharmacists. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 107-112.	0.5	1
41	A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes. Antibodies, 2022, 11, 28.	1.2	1
42	A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. Journal of Antimicrobial Chemotherapy, 2021, 76, 2890-2893.	1.3	0